In vitro bactericidal activity of antibiotic combinations against clinical isolates of Mycobacterium chelonae

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 43-47

  Cremades, R ^a   Santos, A ^a   Rodriguez J C ^a,b   Garcia Pachon, E ^a   Ruiz, M ^a   Royo, G ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b Hospital General Universitario   (Spain)

Author keywords

Clarithromycin; Mycobacterium chelonae; Quinolones

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERTAPENEM; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; TOBRAMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; DRUG EFFECT; HEALTH HAZARD; IN VITRO STUDY; MYCOBACTERIUM CHELONEI;

EID: 41149100685     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.43     Document Type: Article

References (27)

1. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15: 716-746.
2. Yang SC, Hsueh PR, Lai HC et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2003; 47: 1958-1962.
3. Rodriguez Diaz JC, Lopez M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous Mycobacteria. Int J Antimicrob Agents 2003;21:585-8.
4. Heginbothom ML. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment. Int J Tuberc Lung Dis. 2001;5:539-45.
5. Ruiz M, Rodriguez JC, Escribano I, Garcia-Martinez J, Rodriguez-Valera F, Royo G. Application of molecular biology techniques to the diagnosis of nontuberculous mycobacterial infections. APMIS 2001;109:857-64.
6. Knapp C, Moody JA. Test to assess bactericidal activity. In: Isenberg HD, ed. Clinical microbiology procedures handbook. American Society for Microbiology: Washington; 1992: 5.16.1-5.16.33.
7. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am Respir Crit Care Med. 2003;167:1348-54.
8. Burman WJ. The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Am J Med Sci 1997;313:355-63.
9. Vemulapalli RK, Cantey JR, Steed LL, Knapp TL, Thielman NM. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonea infection: case report and literature review. J Infect 2001; 43: 163-168.
10. Rinder H. Hetero-resistance: an under-recognised confounder in diagnosis and therapy? J Med Microbiol. 2001;50:1018-20.
11. Rodriguez JC, Cebrian L, Lopez M, Ruiz M, Royo G. Mutant prevention concentration: a new tool for choosing treatment in nontuberculous mycobacterial infections. Int J Antimicrob Agents 2004;24:352-6.
12. Rodriguez JC, Garcia-Pachon E, Ruiz M, Royo G. Drug susceptibility of the Mycobacterium genus: in vitro tests and clinical implications. Current Clin Pharmacol 2006; 1: 277-289.
13. Aberg JA, Wong MK, Flamm R, Notario GF, Jacobson MA. Presence of macrolide resistance in respiratory flora of HIV-infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis. HIV Clin Trials 2001;2:453-9.
14. Fodor T. How drug resistance emerges as a result of poor compliance. Int J Tuberc Lung Dis. 1999;3:174.
15. Bermudez LE, Petrofsky M, Kolonoski P, Young LS. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrob Agents Chemother. 1998;42:180-3.
16. Wallace RJ Jr, Meier A, Brown BA et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 1996;40:1676-81.
17. Nash KA. Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. Antimicrob Agents Chemother 2001;45:1607-14.
18. Burman WJ, Stone BL, Rietmeijer CA, Maslow J, Cohn DL, Reves RR. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. AIDS 1998;12:1309-15.
19. Shafran SD. Clarithromycin prophylaxis for disseminated Mycobacterium avium complex infection - efficacy and acquired resistance. Clin Infect Dis 1998;27:813-5.
20. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156: S1-S25.
21. Subcommittee of the Join Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 2000; 55: 210-218.
22. Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28: 807-811.
23. Brown-Elliott BA, Wallace RJ Jr, Crist CJ, Mann L, Wilson RW. Comparison of in vitro activities of garifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother 2002; 46: 3283-3285.
24. Brown-Elliott BA, Wallace RJ Jr, Blinkhorn R, Crist CJ, Mann LB. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis 2001; 33: 1433-1434.
25. Kyle SD, Porter WM. Mycobacterium chelonae infection successfully treated with oral clarithromycin and linezolid. Br J Dermatol 2004; 151: 1101.
26. Vera-Cabrera L, Brown-Elliott BA, Wallace RJ Jr et al. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria. Antimicrob Agents Chemother 2006; 50:4027-4029.
27. Wallace RJ Jr, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45:764-7.